Cancer treatment mostly leads to ADR’s (Adverse Drug Reaction), which
impacts the patient’s recovery and leads to some permanent disabilities or
death. For kids who are continuing, cancer treatment has a high risk of severe
adverse drug reactions.
Pharmacogenomics is the research about the part of the genome in response to
drugs. The name represents the combination of both genomics and
pharmacology. This study observes how an individual’s genetics is affected in
response to drug use. The main objective of pharmacogenomics is to develop
and maximize treatments and therapy with an individual patient’s genotypes
to ensure the maximum benefit is obtained with less adverse effects.
Martin Ester said that adverse drug reactions is dangerous in adults, but in
kids, it is three times more life-threatening. Approximately 75% of childhood
cancer patients develop chronic conditions, and approximately 42% grow life-
threatening adverse drug reactions from cancer treatment. Learn more about Data Science Course in Chennai
Martin Ester is on a research team that was recently awarded $9.9 million
from Canada’s applied research project competition in 2017. B.C led the
research team. Hospitals Bruce Carleton and Colin Ross are researching how
different patients respond to medicines that alter their genes, which is
popularly known as pharmacogenomics.
Martin Ester was awarded as a member of the Royal Society of Canada in
2019, the nation’s largest academic honor, known as the world’s data mining
scholar in 2016. He is currently leading a project to mine genomic adverse
drug reactions data using the machine learning method.
He later said that he has collected more than 6125 DNA samples and has
reports of corresponding medication uses and adverse drug reactions results
recorded in a medical database. This is just the beginning of the new
technology that will help us find new links between ADR and genetics and help
us make algorithms to forecast a child’s type of suffering during their cancer
Medical experts could use this new technology to evaluate children’s
sensitivity towards ADR’s beforehand and allow time for special treatments
that can prevent ADR’s and save lives.
INITIATING ATTAINABLE PHARMACOGENOMIC SCREENING
CENTERS IN CANADA
Presently, the data of 6125 DNA samples are more than enough for the
project’s developmental step. The researchers will need more data that will be
more illustrative of the population and make sure that ADR’s are correctly
predicted to move ahead. But, pharmacogenomic testing is difficult because it
initially needs both the physician and patients to assist in decision making.
The researchers are also making advanced tools and maintaining resources to
support information translation and are using their discovery for mass uses.
The pharmacogenomic testing facilities across Canada are currently
expanding. To assist them in their research, they have hoped that their
research findings would help establish pharmacogenomic screening centers
across the country.
Martin Ester further said that he wants to provide the most-needed easy
access to pharmacogenomic testing centers in oncology departments across
Canada. This data will help make personalized medicines to better the
individuals’ well-being. Click here for more details Data Science Course in Pune